http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2681050-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d01227a7111c7565c8a5a1906a182c9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789 |
| filingDate | 2013-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f5a8f29ef85e303ffb4609f6a7a1ed2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3c20e27c32dafb7ec3f8ed3d7e0018a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b33dacc8bd280984c96cae3a8bfbe4ac |
| publicationDate | 2018-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2681050-T3 |
| titleOfInvention | Bruton tyrosine kinase inhibitors for hematopoietic mobilization |
| abstract | A pharmaceutical composition comprising a Bruton tyrosine kinase inhibitor (BTK) for use in restoring or improving hematopoiesis in a subject in need and for reducing the extent or duration of leukopenia and neutropenia as a result of chemotherapy, radiation therapy or accidental exposure to radiation in a subject, said use comprising administering to said subject said pharmaceutical composition in an amount effective to mobilize hematopoietic stem and / or progenitor cells in the peripheral blood of said subject, in which the BTK inhibitor is select from formula I: ** Formula ** in which: La is CH2, O, NH or S; Ar is a substituted or unsubstituted aryl, unsubstituted phenyl, or substituted or unsubstituted heteroaryl; Y is a 4-, 5-, 6-, or 7-membered cycloalkyl ring, or Y is a 4-, 5-, 6-, or 7-membered monocyclic nitrogen-containing heterocycloalkyl ring; Z is C (> = O), OC (> = O), NHC (> = O), NRC (> = O), C (> = S), S (> = O) x, OS (> = O ) x, NHS (> = O) x, where x is 1 or 2; R7 and R8 are independently selected from H, unsubstituted C1-C4 alkyl, substituted C1-C4 alkyl, C1-C6 alkoxyalkyl, C1-C8 alkylaminoalkyl, phenyl, C1-C4 unsubstituted heteroalkyl, C1- heteroalkyl Substituted C4, unsubstituted C3-C6 cycloalkyl, substituted C3-C6 cycloalkyl, unsubstituted C2-C6 heterocycloalkyl and substituted C2-C6 heterocycloalkyl; or R7 and R8 taken together form a bond; R6 is H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, C1-C6 alkoxyalkyl, C1-C8 alkylaminoalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, C2- heterocycloalkyl Substituted or unsubstituted C8, substituted or unsubstituted heteroaryl, C1-C4 alkyl (aryl), C1-C4 alkyl (phenyl), C1-C4 alkyl (heteroaryl), C1-C4 alkyl (C3-C8 cycloalkyl), or C1 alkyl -C4 (C2-C8 heterocycloalkyl), or C1-C8 alkylaminoalkyl; R is H, or C1-C6 alkyl and pharmaceutically acceptable solvates or pharmaceutically acceptable salts thereof. |
| priorityDate | 2012-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 320.